The Role of Oncolytic Viruses in the Treatment of Melanoma.

Autor: Bayan CY; Columbia University College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, 10032, USA., Lopez AT; Columbia University College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, 10032, USA., Gartrell RD; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA., Komatsubara KM; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA., Bogardus M; Columbia University College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, 10032, USA., Rao N; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA., Chen C; Columbia University College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, 10032, USA., Hart TD; Columbia College, Columbia University, New York, NY, 10027, USA., Enzler T; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA., Rizk EM; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA., Pradhan JS; Department of Pathology, Columbia University Medical Center, New York, NY, 10032, USA., Marks DK; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA., Geskin LJ; Department of Dermatology, Columbia University Medical Center, New York, NY, 10032, USA., Saenger YM; Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA. yms4@cumc.columbia.edu.
Jazyk: angličtina
Zdroj: Current oncology reports [Curr Oncol Rep] 2018 Aug 25; Vol. 20 (10), pp. 80. Date of Electronic Publication: 2018 Aug 25.
DOI: 10.1007/s11912-018-0729-3
Abstrakt: Purpose of Review: Oncolytic virotherapy is a new approach to the treatment of cancer and its success in the treatment of melanoma represents a breakthrough in cancer therapeutics. This paper provides a review of the current literature on the use of oncolytic viruses (OVs) in the treatment of melanoma.
Recent Findings: Talimogene laherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting. Several other OVs are at various stages of clinical and pre-clinical development for the treatment of melanoma. Reports from phase Ib-III clinical trials combining T-VEC with checkpoint blockade are encouraging and demonstrate potential added benefit of combination immunotherapy. OVs have recently emerged as a standard treatment option for patients with advanced melanoma. Several OVs and therapeutic combinations are in development. Immunooncolytic virotherapy combined with immune checkpoint inhibitors is promising for the treatment of advanced melanoma.
Databáze: MEDLINE
Externí odkaz: